Erik Tillman, PhD
About Erik Tillman, PhD
Erik Tillman, PhD, serves as the Associate Director of Translational Biology and Pharmacology at Akero Therapeutics, where he focuses on bridging laboratory research and patient care in biotechnology. He has a robust background in scientific research and entrepreneurship, with previous roles at Vida Ventures, LLC, and the Massachusetts Institute of Technology.
Work at Akero Therapeutics
Erik Tillman currently serves as the Associate Director of Translational Biology and Pharmacology at Akero Therapeutics, a position he has held since 2022. Prior to this role, he was a Principal Scientist at the same organization from 2020 to 2022. His career at Akero began as a Senior Scientist and Associate Director of Scientific Strategy from 2018 to 2020. In these roles, he has focused on bridging laboratory research with patient care, particularly in the areas of liver fibrosis and metabolic diseases.
Education and Expertise
Erik Tillman earned his Doctor of Philosophy (PhD) from the Massachusetts Institute of Technology (MIT) in the Department of Biology, where he was a PhD candidate in Dennis Kim's Lab from 2012 to 2018. He also holds a Bachelor of Arts (B.A.) from Williams College, completed from 2006 to 2010. His academic background is complemented by extensive research experience in biotechnology, particularly in the development and commercialization of life sciences advancements.
Background
Before joining Akero Therapeutics, Erik Tillman worked in various capacities within the biotechnology and academic sectors. He served as a Fellow at Vida Ventures, LLC for six months in 2018. His previous roles include Chief Scientific Officer at Disease Diagnostic Group, Inc. from 2015 to 2018, and Research Technician at Dana-Farber Cancer Institute from 2010 to 2012. He has also contributed to educational settings as a Teaching Assistant at both Williams College and MIT.
Achievements
Erik Tillman has co-authored several publications focusing on Efruxifermin's impact on liver fibrosis and metabolic diseases. His research includes studies on the safety and efficacy of Efruxifermin in combination with a GLP-1 receptor agonist. He has participated in the Keystone Symposium on MASH and fibrosis, highlighting his involvement in significant discussions within the field of biotechnology.